Charles River Laboratories International's (CRL) mid-term sales growth has structurally slowed down, a view that is supported by recent results and outlook, peer read-across, pricing trends and updated market analysis, UBS Securities said in a note Friday.
The brokerage said it sees various pressures to the mid-term sales growth in the company's discovery and safety assessment segment, which comprises about 60% of its sales.
Among these pressures are budget pressures at big pharma and underappreciated pricing pressures, UBS said.
"We remain constructive on Charles River's positioning as a key enabler to biopharma, and its opportunity to execute on cost reductions," UBS said.
UBS downgraded Charles River to neutral from buy and cut its price target to $185 from $250.
Price: 165.17, Change: -0.63, Percent Change: -0.38
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。